Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on May 1, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Avadel’s 2025 audited statements show a sharp financial inflection: revenue $279.1M, net income $64.7M, and operating income $70.2M.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Avadel’s 2025 audited statements show a sharp financial inflection: revenue $279.1M, net income $64.7M, and operating income $70.2M
- Cash and equivalents rose to $165.4M from $51.4M, supported by $98.0M operating cash flow
- Alkermes completed its acquisition on February 12, 2026 for $21.00 per share plus a potential $1.50 CVR
- Avadel became a wholly owned Alkermes subsidiary, with Nasdaq delisting effective February 23, 2026
- LUMRYZ remains the sole commercialized product, while valiloxybate and idiopathic hypersomnia development expand strategic upside and execution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.